HSPA5, RCN1, CLGN, and TXD15 need to be validated using an assay method compatible with use in a central lab (e.g., ELISA) in a large prospective study of patients with advanced-stage cancer before these proteins can be used to guide anticoagulation prophylaxis. The gene discussed is CLGN; the disease is cancer.